Tom Shelly

Tom Shelly has extensive work experience in various roles in the biotech and clinical research industry. Tom is currently the Global Lead Clinical & Logistics Management at GRI Bio, Inc. Prior to this, they served as the COO/CFO of Attenuate Therapeutics Ltd. Tom held the position of General Manager at Sublimity Therapeutics, where they led the global Phase 2b clinical trial for the treatment of Moderate to Severe Ulcerative Colitis. Before that, they worked at Cambridge Clinical Research as a Consultative Clinical Development Project Manager and also served as the Founder and Managing Director. Additionally, they held the position of Vice President of Finance and Operations at Tecan.

Tom Shelly obtained a Master of Business Administration (MBA) degree in Business Administration and Management, General from UNC Kenan-Flagler Business School between 1993 and 1995. Tom also holds the certification of Fellow of The Institute of Chartered Accountants in Ireland, which they obtained in 1983.